Lophius Biosciences Closes Additional Financing Round with Current Investors Totaling 1.4 Million EUR
“We are very pleased to have been able to conclude this financing round with our existing investors in such a short time. Subsequent to the successful establishment of the company over the past year and the imminent conclusion of the test developments for our patented T-Track © CMV/EBV Tests, these new financial resources allow us to prepare for market entry of these tests from the beginning of 2012 with an effective team. Beyond this, we will now intensify the development of additional innovative diagnostic tests based on our patented technology platforms,” said Dr. Michael Lutz, CEO of Lophius Biosciences.
“With the aid of the financing round in the precious year Lophius Biosciences has been able to develop from an essentially academic research company into a small, highly innovative and fully integrated diagnostic company within a very short timeframe. We are absolutely convinced that the Lophius’ technologies and the products have a great potential to provide patients with large diagnostic benefits in our disease areas,” amended Bertram Gilka-Bötzow of S-Refit, Lophius Biosciences’ lead investor.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.